Humanigen

Humanigen Debt / Assets

Delisted

Debt-to-Assets Ratio of Humanigen (HGENQ) as of Oct 11, 2026.

Debt / Assets

0.00

Last updated:

Debt-to-Assets Ratio of Humanigen is 2022 0.00 . Debt-to-Assets Ratio of Humanigen was 2021 0.35 . It decreases by % lower compared to the previous year.

The Humanigen Debt / Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt / Assets
Date
Debt / Assets
Jan 1, 2015
0.00 USD
Jan 1, 2016
0.91 USD
Jan 1, 2017
11.60 USD
Jan 1, 2018
2.55 USD
Jan 1, 2019
12.48 USD
Jan 1, 2020
0.00 USD
Jan 1, 2021
0.35 USD
Jan 1, 2022
0.00 USD
The Humanigen Debt / Assets history
YEARDebt / AssetsYoY
0.00-100.00%
0.35—
0.00-100.00%
12.48+388.53%
2.55-77.97%
11.60+1,176.14%
0.91—
0.00-100.00%
0.25—
Access this data via the Eulerpool API

Humanigen Stock analysis

What does Humanigen do? Humanigen Inc is a pharmaceutical company specializing in the discovery, development, and marketing of drugs, therapies, and solutions in the field of medical research. The company was originally founded in 2000 and is headquartered in Burlingame, California. One major focus of Humanigen Inc is the treatment of severe and life-threatening diseases such as cancer or HIV/AIDS that have not been sufficiently addressed by other medications. The company has developed a range of special technologies that enable it to develop innovative and effective therapies and drugs. An important aspect of Humanigen Inc's business model is collaboration with other companies, institutions, and research facilities worldwide. Through partnerships and cooperation, the company is able to cover the entire spectrum of research and development, allowing it to develop treatment options even faster and more effectively. Humanigen Inc has several different divisions and products designed for various applications. An important subsidiary of the company is the Humanigen Center for HIV Cure Research, which specifically focuses on combating HIV. There, the company works closely with scientists, researchers, and partners to develop new and innovative treatment options. Another important product of Humanigen Inc is the drug Lenzilumab. Lenzilumab is an antibody used to treat severe and life-threatening diseases such as cancer and COVID-19. Lenzilumab has shown great promise in clinical trials and could be the key to developing new and effective treatment options. In addition, Humanigen Inc has filed a variety of patents that enable it to develop new and innovative technologies in medical research. Many of these technologies are also licensed by other companies and research institutions, promoting the growth and expansion of Humanigen Inc. In recent years, the company has also placed a major focus on the field of digital technology. By utilizing big data, artificial intelligence, and other digital technologies, Humanigen Inc is able to develop new therapy options even faster and more effectively, catering specifically to the needs of patients and doctors. Overall, Humanigen Inc is an innovative and rapidly growing company focused on the development of new and effective treatment options for serious diseases. Through collaboration with other companies and institutions, the development of new technologies, and a targeted focus on the needs of patients and doctors, the company is able to respond even faster and more effectively to challenges in the field of medical research. Humanigen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Humanigen stock

On Eulerpool you can find the complete historical development of Debt-to-Assets Ratio Humanigen since 2006 – with annual values, charts, and detailed analysis.

The Debt-to-Assets ratio measures what percentage of a company's assets are financed through debt. Higher ratios indicate greater financial risk.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt-to-Assets Ratio's Humanigen with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — Humanigen

All Key Metrics — Humanigen